LOADING
Comparing JPMorgan Chase (JPM) and Merck & Company (MRK) across the Financials and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JPM | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $807.6B | $280.2B |
| P/E Ratio | 14.4 | 32.0 |
| Forward P/E | 13.8 | 22.0 |
| PEG Ratio | 1.60 | 5.18 |
| EPS | $20.88 | $3.55 |
| Revenue Growth (YoY) | 12.7% | 4.9% |
| Profit Margin | 33.9% | 13.6% |
| Return on Equity | 16.5% | 18.9% |
| Dividend Yield | 1.94% | 2.92% |
| Beta | 1.02 | 0.20 |
| 52-Week High | $334.16 | $124.22 |
| 52-Week Low | $251.12 | $70.74 |
| Volume | -- | -- |
JPMorgan Chase is the larger company by market capitalization. JPMorgan Chase trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. JPMorgan Chase has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.